Working… Menu

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02111317
Recruitment Status : Completed
First Posted : April 11, 2014
Last Update Posted : April 11, 2014
Janssen Biotech, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. )

Brief Summary:
The purpose of this study is to evaluate the effect of verapamil, a P-glycoprotein (P-gp) inhibitor, on the pharmacokinetics of ASP015K. This study will also assess the safety and tolerability of ASP015K administered alone and also and in combination with verapamil.

Condition or disease Intervention/treatment Phase
Healthy Subjects Pharmacokinetics of ASP015K Drug: ASP015K Drug: verapamil Phase 1

Detailed Description:
Eligible subjects will be admitted to the clinical unit on day -1 and remain confined until day 15.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1, Open-label, Single-Sequence, Crossover Drug Interaction Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects
Study Start Date : October 2013
Actual Primary Completion Date : November 2013
Actual Study Completion Date : November 2013

Arm Intervention/treatment
Experimental: ASP015K and verapamil
Single dose of ASP015K, then repeat dose of verapamil, then a second single dose of ASP015K while continuing verapamil
Drug: ASP015K

Drug: verapamil
Other Name: CALAN®

Primary Outcome Measures :
  1. Pharmacokinetics of ASP015K: Maximum concentration (Cmax) [ Time Frame: Days 1-4 and Days 12-15 ]
  2. Pharmacokinetics of ASP015K: Area under the concentration-time curve (AUC) from time of dosing to the last quantifiable concentration (AUClast) [ Time Frame: Days 1-4 and Days 12-15 ]
  3. Pharmacokinetics of ASP015K: AUC from the time of dosing extrapolated to time infinity (AUCinf) [ Time Frame: Days 1-4 and Days 12-15 ]

Secondary Outcome Measures :
  1. Pharmacokinetic profile of ASP015K: time of maximum plasma concentration (tmax), terminal elimination half-life (t½), apparent total systemic clearance (CL/F), and apparent volume of distribution during the terminal elimination phase (Vz/F) [ Time Frame: Days 1-4 and Days 12-15 ]
  2. Pharmacokinetic profile of ASP015K metabolites: Cmax, AUClast, AUCinf, tmax and t½ [ Time Frame: Days 1-4 and Days 12-15 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject has a Body Mass Index (BMI) range of 18.5-32.0 kg/m2, inclusive, and must weigh at least 50 kg
  • Subject must be capable of swallowing multiple tablets
  • Subject agrees not to participate in another investigational study while on treatment

Exclusion Criteria:

  • Subject has a known or suspected hypersensitivity to verapamil, ASP015K, or any components of the formulations used.
  • Subject has any of the liver function tests above the upper limit of normal (ULN)
  • Subject has any clinically significant history of allergic conditions (including drug allergies, asthma, eczema or anaphylactic reactions, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
  • Subject has any history or evidence of any clinically significant cardiovascular, GI, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory) infection, or fungal (noncutaneous) infection within 1 week prior to day -1.
  • Subject has any clinically significant abnormality following physical examination, ECG, such as sick sinus syndrome, second- or third-degree atrioventricular block, or atrial flutter/atrial fibrillation, or clinical laboratory tests
  • Subject has a mean pulse < 50 or > 90 beats per minute (bpm); mean systolic blood pressure (SBP) < 100 or > 140 mmHg; mean diastolic blood pressure (DBP) < 60 or > 90 mmHg (measurements taken in triplicate after subject has been resting in sitting position for 5 minutes)
  • Subject has a mean QTcF interval of > 430 msec (for males) and > 450 msec (for females)
  • Subject has used any prescribed or nonprescribed drugs (including vitamins, natural and herbal remedies, e.g., St. John's Wort) in the 2 weeks prior to study drug administration, with the exception of hormone replacement therapy (HRT) and intermittent acetaminophen (no more than 2 g per day)
  • Subject has smoked or has used tobacco-containing products and nicotine or nicotine-containing products in the past 6 months
  • Subject has a history of consuming more than 14 units of alcoholic beverages per week within 6 months prior to screening or has a history of alcoholism or drug/chemical substance abuse within past 2 years prior to screening (Note: one unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits)
  • Subject has a positive test for alcohol, drugs of abuse, or cotinine
  • Subject anticipates an inability to abstain from xanthine (e.g., caffeine), grapefruit, Seville oranges (including marmalade), star fruit, or any products containing these items from 72 hours prior to day -1 and throughout the duration of the study
  • Subject has used any inducer of metabolism (e.g., barbiturates, rifampin) in the past 3 months prior to day -1
  • Subject has had any significant blood loss, donated 1 unit (450 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within past 7 days
  • Subject has a positive test for hepatitis B surface antigen (HBsAg), anti-hepatitis A virus (Immunoglobulin [Ig] M), anti-hepatitis C virus (HCV), hepatitis B core antibody or anti-human immunodeficiency virus (HIV) type 1 or type 2
  • Subject has a positive tuberculosis (TB) skin test, Quantiferon Gold® test or T-SPOT® test
  • Subject received any vaccine within 60 days prior to study drug administration
  • Subject has an absolute neutrophil count (ANC) < 2000 cells/mm3 or a creatine phosphokinase (CPK) > 1.5 x ULN
  • Subject has had major gastrointestinal (GI) surgery or has a medical condition, which may inhibit the absorption and/or metabolism of study drug
  • Subject has participated in any interventional clinical study or has been treated with any investigational drugs within 30 days or 5 half-lives of the drug, whichever is longer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02111317

Layout table for location information
United States, California
Glendale, California, United States, 91206
Sponsors and Collaborators
Astellas Pharma Global Development, Inc.
Janssen Biotech, Inc.
Layout table for investigator information
Study Chair: Global Clinical Pharmacology Lead Astellas Pharma Global Development, Inc.
Layout table for additonal information
Responsible Party: Astellas Pharma Global Development, Inc. Identifier: NCT02111317    
Other Study ID Numbers: 015K-CL-PK04
First Posted: April 11, 2014    Key Record Dates
Last Update Posted: April 11, 2014
Last Verified: April 2014
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Global Development, Inc. ):
Healthy Subjects
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Vasodilator Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors